Adjuvants are usually a fundamental part of a vaccine formulation due to their ability to increase immunogenicity, but their safety and efficacy must be established in preclinical studies. In this sense, we evaluated Emulsivant 70, a new ready‐to‐use adjuvant based on water‐in‐oil (W/O) emulsion for veterinary vaccines. Its performance was compared with the commercial adjuvant Montanide ISA 70 in mice immunized with tetanus toxoid (TT) and inactivated influenza PR8. No substantial changes in renal or hepatic biochemical markers (urea, creatinine, alanine aminotransferase [ALT], and aspartate aminotransferase [AST]) were observed for any formulation. Emulsivant 70 induced lower reactogenicity at the injection site than Montanide ISA 70. Both adjuvants enhanced IgG and IgG1 responses, but Emulsivant 70 promoted a faster increase in total IgG for both antigens. IFN‐γ levels increased similarly across adjuvanted groups. Following the influenza A challenge, all PR8‐immunized were fully protected. Overall, this study provides the first evidence that Emulsivant 70 is a safe adjuvant that elicits less local reactivity and achieves immunogenicity comparable to Montanide ISA 70, while inducing a faster humoral response. These findings support Emulsivant 70 as a promising alternative for the development of veterinary vaccines.